

## 2020 South Dakota Legislature

**House Bill 1008****AMENDMENT 1008K FOR THE SENATE BILL**

1 ~~An Act to implement a plan for hemp in South Dakota.~~ legalize the growth,  
2 production, and transportation of industrial hemp in the state, to make an  
3 appropriation therefor, and to declare an emergency.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF SOUTH DAKOTA:

5 **Section 1.** That a NEW SECTION be added:

6 **38-35-1. Definitions.**

7 Terms used in this chapter mean:

8 (1) "Department," the Department of Agriculture;

9 (2) "Hemp" or "industrial hemp," the plant Cannabis sativa L. and any part of that  
10 plant, including the seeds thereof and all derivatives, extracts, cannabinoids,  
11 isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9  
12 tetrahydrocannabinol concentration of not more than three-tenths of one percent  
13 on a dry weight basis;

14 (3) "Key participant," a sole proprietor, a partner in a partnership, or a person with  
15 executive managerial control in a corporation or limited liability company;

16 (4) "Industrial hemp product," a finished manufactured product, or consumer product  
17 containing cannabidiol that is packaged for individual sale, with a delta-9  
18 tetrahydrocannabinol concentration of not more than three-tenths of one percent,  
19 derived from or made by processing industrial hemp;

20 (5) "Lot," a contiguous area in a field containing the same variety or strain of hemp  
21 throughout the area;

22 (6) "Process" or "processing," to convert or converting industrial hemp into industrial  
23 hemp product;

- 1        (7) "Processor," a person who processes industrial hemp;  
2        (8) "Produce" or "producing," to grow or growing hemp plants in the field for  
3            processing;  
4        (9) "Secretary," the secretary of the Department of Agriculture; and  
5        (10) "Transporter," any person transporting, hauling, or delivering hemp, but not  
6            industrial hemp product or sterilized seeds that are incapable of beginning germination.

7        **Section 2.** That a NEW SECTION be added:

8            **38-35-2. Purchasing, receiving, or obtaining industrial hemp--License**  
9            **required--Penalty.**

10            No person may purchase, receive, or obtain industrial hemp, other than industrial  
11            hemp product, for planting, storing, propagating, producing, or processing unless the  
12            person has a license as provided by this chapter or is working under contract with or under  
13            the direction of a licensee. The licensee is responsible, either civilly or criminally, for any  
14            person working under contract with or under the direction of a licensee for all sections of  
15            this chapter.

16            It shall be a Class 2 misdemeanor to purchase, receive, or obtain industrial hemp,  
17            other than industrial hemp product, for planting, storing, propagating, producing, or  
18            processing without a license. No unlicensed person is subject to criminal penalties for  
19            possession or distribution of hemp seed.

20            A person, whether or not licensed, who possesses or distributes a product  
21            determined to meet the definition of marijuana is subject to prosecution and penalties for  
22            possession or distribution of marijuana under chapter 22-42.

23        **Section 3.** That a NEW SECTION be added:

24            **38-35-3. Application for grower license.**

25            After the department receives approval by the United States Secretary of  
26            Agriculture for the state plan submitted pursuant to § 38-35-15, any person seeking to  
27            purchase, receive, or obtain industrial hemp, other than industrial hemp product, for  
28            planting, storing, propagating, or producing shall apply to the secretary for a grower  
29            license on an application form prescribed by the department and submit a nonrefundable  
30            annual application fee. The department shall establish a sixty-day period in which an  
31            application must be received. The secretary shall deposit fees collected under this chapter  
32            in the hemp regulatory program fund.

1           No application for licensure to plant, grow, or produce industrial hemp may be for  
2           less than five contiguous outdoor acres.

3   **Section 4.** That a NEW SECTION be added:

4           **38-35-4. Application for processor license--Fee--Location notice.**

5           After the department receives approval by the United States Secretary of  
6           Agriculture for the state plan submitted pursuant to § 38-35-15, any person seeking to  
7           purchase, receive, or obtain industrial hemp, other than industrial hemp product, for  
8           processing shall apply to the secretary for a processor license on an application form  
9           prescribed by the department and submit a nonrefundable annual application fee. The  
10          applicant may submit an application form for a processor license at any time. The  
11          secretary shall deposit fees collected under this chapter in the hemp regulatory program  
12          fund.

13          The applicant shall provide to the department the street address, legal description,  
14          and global positioning system coordinates for any location where hemp will be processed  
15          under the processor's license and certify that any location where hemp is to be processed  
16          is under the control of the applicant. A processor licensee shall provide notice of any  
17          change in ownership or location to the department within two days of a change. A change  
18          of ownership or location automatically invalidates the license, and a new license must be  
19          obtained.

20   **Section 5.** That a NEW SECTION be added:

21          **38-35-5. Criminal background check--Denial of license for conviction--**  
22          **Licensure exemption.**

23          Each applicant for any license under this chapter, key participant, and landowner,  
24          if the applicant is the lessee, shall submit to a state and federal criminal background  
25          investigation by means of fingerprint checks by the Division of Criminal Investigation and  
26          the Federal Bureau of Investigation. Upon application for a license, the department shall  
27          submit the completed fingerprint cards to the division. Upon completion of the criminal  
28          background check, the division shall forward to the department all information obtained  
29          as a result of the criminal background check. This information shall be obtained prior to  
30          licensure of the applicant. All costs or fees associated with the criminal background checks  
31          are the responsibility of the applicant. Information provided to the department under this  
32          section is confidential, is not public record, and is exempt from the provisions of chapter  
33          1-27. However, the department may share this information with law enforcement and the

1 Department of Public Safety. Failure to submit to or cooperate with a criminal background  
2 check is grounds for denial or revocation of a license. The secretary may deny licensure if  
3 any applicant, key participant, or landowner has been convicted of a misdemeanor or  
4 felony relating to a controlled substance or marijuana under state or federal law within  
5 the previous ten years. Licensure under this chapter is not required for employees of the  
6 state of South Dakota when performing official duties.

7 **Section 6.** That a NEW SECTION be added:

8 **38-35-6. Hemp regulatory program fund--Purpose--Expenditures.**

9 There is hereby created within the state treasury the hemp regulatory program  
10 fund, into which all application fees, license fees, inspection fees, and other fees or  
11 revenue paid to the state from the operation of the hemp regulatory program shall be  
12 deposited. All moneys in the fund created in this section shall be used for the purpose of  
13 administering the hemp regulatory program. Interest earned on money in the fund shall  
14 be deposited into the fund. Expenditures from the fund shall be appropriated through the  
15 normal budget process.

16 **Section 7.** That a NEW SECTION be added:

17 **38-35-7. License issuance--Denial, revocation, or suspension--Contested**  
18 **case.**

19 If the applicant has completed the application to the satisfaction of the secretary,  
20 paid the application fee, returned a criminal background check compliant with § 38-35-5,  
21 and is eligible for a license under this chapter, the secretary shall issue the license upon  
22 receipt of an annual license fee and upon the licensee's agreement and affirmance that as  
23 a continuing condition of licensure, the department shall have unlimited access to all lots  
24 or licensed locations processing hemp without prior notice to the licensee or the need to  
25 obtain a search warrant or court order for access to enforce the provisions of this chapter.

26 A grower license issued under this chapter is valid for fifteen months from the date  
27 of issuance. A processor license issued under this chapter expires on December thirty-first  
28 in the calendar year for which it was issued.

29 The department may deny, revoke, or suspend a license of any person who:

- 30 (1) Violates any provision of this chapter or administrative rule promulgated under the  
31 authority of this chapter;  
32 (2) Violates any rule set forth by the United States Department of Agriculture regarding  
33 industrial hemp;

1 (3) Provides false or misleading information in connection with any application required  
2 by this chapter;

3 (4) Has been convicted of a misdemeanor or felony relating to a controlled substance  
4 or marijuana under state or federal law within the previous ten years; or

5 (5) Has been charged with or convicted of a misdemeanor or felony relating to a  
6 controlled substance or marijuana under state or federal law since the most recent  
7 criminal background check.

8 Any person whose license is denied, revoked, or suspended under this section may  
9 request a hearing pursuant to chapter 1-26.

10 **Section 8.** That a NEW SECTION be added:

11 **38-35-8. Planting--Documentation to be filed--Contents.**

12 Within thirty days of planting, each grower licensee under this chapter shall file  
13 with the department documentation as required by the secretary in order to identify the  
14 type and variety of each hemp seed planted with its corresponding lot. Any documentation  
15 provided under this section is not an open record pursuant to chapter 1-27 and may not  
16 be disclosed except to the Department of Public Safety or law enforcement. The  
17 department may make publicly available a list of all types and varieties of planted hemp  
18 seed submitted to the department.

19 **Section 9.** That a NEW SECTION be added:

20 **38-35-9. Entrance by department--Consent--Fee--Inspection, confiscation,**  
21 **and disposal--Costs--Liability for destruction--Records.**

22 The secretary shall contract with the Department of Public Safety to conduct  
23 inspections and sampling of each lot and any processor location. The department and the  
24 Department of Public Safety may enter on any land or other property where hemp is  
25 grown, produced, stored, or processed for the purpose of inspections, sample collection,  
26 testing, or investigation while enforcing this chapter. Any person who holds a license under  
27 this chapter is deemed to have given consent to the reasonable search and seizure of any  
28 hemp without a warrant to determine the lawful amount of delta-9 tetrahydrocannabinol  
29 concentration and for enforcement of the provisions of this chapter.

30 The secretary shall assess a grower inspection fee per lot for grower licensees and  
31 shall assess a processor inspection fee per location for processor licensees.

32 Any substance found to be in violation of this chapter is subject to confiscation and  
33 disposal at the direction of the Department of Public Safety. Any costs arising from the

1 destruction, confiscation, or disposal are the responsibility of the grower, producer,  
2 processor, or owner of the substance. The state is not liable for any confiscation, seizure,  
3 disposal, or destruction of any substance carried out under this chapter. Any testing,  
4 inspection, and investigation results shall be provided to the licensee. Notice of any  
5 violation shall be provided to the licensee in writing. Inspection and investigation records  
6 are not open records pursuant to chapter 1-27.

7 **Section 10.** That a NEW SECTION be added:

8 **38-35-10. Inspection timing and procedure--Disclose information.**

9 Every lot of a grower licensee shall be inspected and samples collected no more  
10 than fifteen days before the hemp is harvested. The grower licensee shall contact the  
11 Department of Public Safety prior to harvest in order to ensure a reasonable amount of  
12 time to schedule an inspection. The grower licensee shall be present during the inspection.  
13 No harvested lot of hemp shall be commingled with another harvested lot of hemp or other  
14 material except with documented prior written permission by the department or the United  
15 States Department of Agriculture. No hemp may leave the dominion of control of the  
16 grower licensee until the grower licensee receives a laboratory result from the department  
17 that confirms each lot complies with 7 U.S.C. Chapter 38, Subchapter VII, as provided in  
18 7 C.F.R 990.70(d) and 990.71(d) in effect as of January 1, 2020.

19 Any location of the processor licensee may be subject to random inspection. The  
20 processor licensee shall be present during the inspection.

21 **Section 11.** That a NEW SECTION be added:

22 **38-35-11. Promulgation of rules--Fees.**

23 The department shall promulgate rules, pursuant to chapter 1-26, to:

- 24 (1) Establish application, application form, licensure, and renewal procedures;  
25 (2) Establish requirements to prevent the spread of hemp and hemp seeds from  
26 licensed land areas and provide for the assessment of costs for the remediation  
27 thereof;  
28 (3) Establish criteria and procedures for denial, revocation, or suspension of a license  
29 under this chapter;  
30 (4) Make any modification or addition to the hemp regulatory program in order to  
31 comply with any federal statutes or any rules and regulations regarding hemp  
32 enacted or implemented by the United States Department of Agriculture;

- 1       (5) Establish a nonrefundable annual license application fee not to exceed fifty dollars,  
2       an annual grower license fee not to exceed five hundred dollars, and an annual  
3       processor license fee not to exceed two thousand dollars;  
4       (6) Establish procedures for the collection of planting and harvest data for each lot;  
5       (7) Establish labeling requirements for hemp; and  
6       (8) Establish rules for corrective action for negligent and culpable violations of this  
7       chapter.

8       **Section 12.** That a NEW SECTION be added:

9               **38-35-12. Department of Health--Promulgation of rules.**

10              The Department of Health shall promulgate rules, pursuant to chapter 1-26, to:

- 11       (1) Make any modification or addition to the hemp regulatory program in order to  
12       comply with any federal statutes or any rules and regulations regarding hemp  
13       enacted or implemented by the United States Department of Agriculture; and  
14       (2) Establish testing procedures to determine the lawful amount of delta-9  
15       tetrahydrocannabinol concentration in hemp and certifying results.

16       **Section 13.** That a NEW SECTION be added:

17               **38-35-13. Department of Public Safety--Promulgation of rules.**

18              The Department of Public Safety shall promulgate rules, pursuant to chapter 1-26,  
19       to:

- 20       (1) Make any modification or addition to the hemp regulatory program in order to  
21       comply with any federal statutes or any rules and regulations regarding hemp  
22       enacted or implemented by the United States Department of Agriculture;  
23       (2) Establish inspection procedures and requirements, a grower inspection fee per lot  
24       not to exceed two hundred fifty dollars, and a processor inspection fee per any  
25       processor location not to exceed five hundred dollars;  
26       (3) Establish transportation and permit requirements including assessment of a permit  
27       fee not to exceed twenty-five dollars;  
28       (4) Establish sampling and testing procedures to determine the lawful amount of delta-  
29       9 tetrahydrocannabinol concentration in hemp; and  
30       (5) Establish rules for corrective action for negligent and culpable violations of this  
31       chapter.

32       **Section 14.** That a NEW SECTION be added:

1           **38-35-14. Testing samples--Exceeding concentration--Destruction of lot.**

2           All testing shall be conducted by a laboratory approved by the Drug Enforcement  
3 Administration. If a test reveals a delta-9 tetrahydrocannabinol concentration of more  
4 than three-tenths of one percent but not more than five-tenths of one percent, the licensee  
5 may request a retest at the licensee's expense. If, upon the retesting, the delta-9  
6 tetrahydrocannabinol concentration exceeds three-tenths of one percent, the entire lot  
7 from which the noncompliant sample was collected shall be destroyed as provided by § 38-  
8 35-9.

9           **Section 15.** That a NEW SECTION be added:

10           **38-35-15. State hemp production plan--Submission to United States**  
11 **Department of Agriculture--Establishment of program.**

12           The department shall work with the attorney general to develop a state hemp  
13 production plan and submit the plan to the United States Department of Agriculture for  
14 approval of a program to license the growth, production, storage, processing, and  
15 transportation of industrial hemp in South Dakota. The department shall establish a  
16 program once approval is received by the United States Department of Agriculture.

17           **Section 16.** That a NEW SECTION be added:

18           **38-15-16. Transportation--Consent to search and seizure--Inspection by law**  
19 **enforcement--Penalty.**

20           Any transporter is deemed to have given consent to the reasonable search and  
21 seizure by law enforcement of any hemp without a warrant to determine the lawful amount  
22 of delta-9 tetrahydrocannabinol concentration. Any law enforcement officer may require  
23 any transporter to stop for the purposes of inspection. During a stop, a law enforcement  
24 officer may collect a sample of any hemp for the purpose of testing for any concentration  
25 of delta-9 tetrahydrocannabinol that exceeds three-tenths of one percent on a dry weight  
26 basis. Each sample collected by law enforcement may not exceed eight ounces.

27           It is a Class 2 misdemeanor to transport industrial hemp, but not industrial hemp  
28 product, without appropriate documentation demonstrating compliance with an industrial  
29 hemp program of a federal, state, or tribal authority, in addition to any permit or  
30 documentation required by § 38-35-17.

31           **Section 17.** That a NEW SECTION be added:



1           **38-35-17. Transportation permit requirements--Two types of transportation**  
2 **permits--Required documentation.**

3           An industrial hemp transportation permit is required for any transporter traveling  
4 within or through the state. No person shall transport hemp in this state concurrently with  
5 any other plant material that is not hemp. During transportation, a transporter shall have  
6 the permit in the transporter's physical possession. The Department of Public Safety shall  
7 assess an industrial hemp transportation permit fee and the fee shall be deposited in the  
8 state highway fund. A transporter shall apply for an industrial hemp transportation permit  
9 on a form provided by the Department of Public Safety. The Department of Public Safety  
10 shall make available two types of an industrial hemp transportation permit.

11           Grower licensees pursuant to § 38-35-3 may apply for the grower licensee  
12 transportation permit that shall be exclusively for the transportation of the grower  
13 licensee's industrial hemp from the land as described in the licensee's application to the  
14 storage location as described in the licensee's application. The grower licensee shall  
15 exercise dominion of control over the means of transportation and the storage location at  
16 all times. The grower licensee transportation permit is valid for the length of the grower  
17 license. During transportation pursuant to the grower licensee transportation permit, the  
18 transporter may only be the grower licensee, a key participant, or a person working under  
19 contract with or under the direction of the grower licensee. The transporter shall have in  
20 the transporter's physical possession a copy of the grower license under which the  
21 industrial hemp was grown or produced and a manifest that includes the following  
22 information about the industrial hemp being transported: the specific name and address  
23 of the transporter, the specific lot from which the hemp was harvested, the destination  
24 storage location for the hemp, and the type of vehicle being used.

25           All other transporters shall obtain the general hemp transportation permit. During  
26 transportation pursuant to the general hemp transportation permit, the transporter shall  
27 have in the transporter's physical possession the following documentation:

- 28           (1) A copy of the license under which the industrial hemp was grown or produced;  
29           (2) A laboratory report produced by a Drug Enforcement Administration-registered  
30           laboratory that confirms the lot of origin of all hemp being transported complies  
31           with 7 U.S.C. Chapter 38, Subchapter VII, as provided in 7 C.F.R 990.70(d) and  
32           990.71(d) in effect as of January 1, 2020;  
33           (3) A signed affirmation from the licensee and the transporter that no illicit drugs or  
34           variations of hemp not explicitly authorized by 7 U.S.C. Chapter 38, Subchapter  
35           VII will be transported; and

1 (4) A bill of lading or manifest that includes the shipment contents, the specific name  
2 and address of the transporter, the specific name and address of the origin and lot  
3 of origin, the destination of the shipment, the total weight of the load, and the type  
4 of vehicle being used.

5 A transporter, applying for either type of permit, shall submit a permit form to the  
6 Department of Public Safety at least five business days before the trip. A transporter who  
7 falsifies any information contained on a permit form submitted to the Department of Public  
8 Safety shall be reported to the hemp program under which the industrial hemp being  
9 transported was grown, in addition to any other sanction or criminal charge allowed under  
10 this chapter or title 22. Failure to physically possess an appropriate permit and all proper  
11 documentation is probable cause to believe that the substance being transported is subject  
12 to the provisions of § 38-35-9 and is probable cause to believe that the transporter is  
13 subject to the provisions of chapter 22-42. No political subdivision, agency, law  
14 enforcement officer, or the state is liable for the seizure, spoilage, or destruction of any  
15 hemp shipment that does not meet the requirements of this chapter, regardless of whether  
16 the shipment is later established to be industrial hemp.

17 **Section 18.** That a NEW SECTION be added:

18 **38-35-18. Rules of United States Department of Agriculture.**

19 Each applicant, licensee, key participant, and transporter of industrial hemp, other  
20 than industrial hemp product, shall abide by any rules set forth by the United States  
21 Department of Agriculture.

22 **Section 19.** That a NEW SECTION be added:

23 **38-35-19. Reporting to attorney general.**

24 The attorney general shall annually collect and compile information, statistical and  
25 otherwise, which will, as far as practicable, present an accurate survey and may be useful  
26 in the study of the effect legalizing industrial hemp has had on controlled substance and  
27 marijuana prosecutions in this state, including the extent and character of alleged crimes  
28 not prosecuted or dismissed, the operations of police in drug investigations, the charging  
29 discretion of prosecuting attorneys, and the administration of criminal justice due to the  
30 legalization of industrial hemp. All information collected under this section shall be  
31 reported annually to the Governor and Legislature by December first each year.

32 **Section 20.** That a NEW SECTION be added:

1           **38-35-20. Coordination with other government entities.**

2           The department, Department of Health, and Department of Public Safety may  
3           provide to another state, local, tribal, or federal government entity, any specific licensee  
4           or permittee information as may be necessary to verify the legality or compliance of any  
5           licensee or permittee under this chapter. Application for, and receipt of, a license or permit  
6           under this chapter serves as the applicant's consent to provide information without prior  
7           notice or disclosure to the applicant that the information will be or has been shared.

8           **Section 21.** That a NEW SECTION be added:

9           **38-35-21. Industrial hemp for smoking prohibited--Penalty.**

10           The sale or use of industrial hemp for smoking or inhaling is prohibited. A violation  
11           of this section is a Class 1 misdemeanor.

12           **Section 22.** That § 22-42-1 be AMENDED:

13           **22-42-1. Definition of terms.**

14           Terms used in this chapter mean:

- 15           (1) "Controlled drug or substance," a drug or substance, or an immediate precursor of  
16           a drug or substance, listed in Schedules I through IV. The term includes an altered  
17           state of a drug or substance listed in Schedules I through IV absorbed into the  
18           human body;
- 19           (2) "Counterfeit substance," a controlled drug or substance which, or the container of  
20           labeling of which, without authorization, bears the trade-mark, trade name, or other  
21           identifying mark, imprint, number, or device, or any likeness thereof, of a  
22           manufacturer, distributor, or dispenser other than the person or persons who  
23           manufactured, distributed, or dispensed such substance and which thereby falsely  
24           purports or is represented to be the product of, or to have been distributed by, such  
25           other manufacturer, distributor, or dispenser;
- 26           (3) "Deliver" or "delivery," the actual or constructive transfer of a controlled drug,  
27           substance, or marijuana whether or not there exists an agency relationship;
- 28           (4) "Dispense," to deliver a controlled drug or substance to the ultimate user or human  
29           research subject by or pursuant to the lawful order of a practitioner, including the  
30           prescribing, administering, packaging, labeling, or compounding necessary to  
31           prepare the substance for such delivery, and a dispenser is one who dispenses;
- 32           (5) "Distribute," to deliver a controlled drug, substance, or marijuana. Distribution  
33           means the delivery of a controlled drug, substance, or marijuana;

- 1 (6) "Manufacture," the production, preparation, propagation, compounding, or  
2 processing of a controlled drug or substance, either directly or indirectly by  
3 extraction from substances of natural origin, or independently by means of chemical  
4 synthesis or by a combination of extraction and chemical synthesis. A manufacturer  
5 includes any person who packages, repackages, or labels any container of any  
6 controlled drug or substance, except practitioners who dispense or compound  
7 prescription orders for delivery to the ultimate user;
- 8 (7) "Marijuana," all parts of any plant of the genus cannabis, whether growing or not,  
9 in its natural and unaltered state, except for drying or curing and crushing or  
10 crumbling. The term includes an altered state of marijuana absorbed into the human  
11 body. The term does not include fiber produced from the mature stalks of such  
12 plant, or oil or cake made from the seeds of such plant. The term does not include  
13 the plant Cannabis sativa L. and any part of that plant, including the seeds thereof  
14 and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of  
15 isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration  
16 of not more than three-tenths of one percent on a dry weight basis;
- 17 (8) "Practitioner," a doctor of medicine, osteopathy, podiatry, dentistry, optometry, or  
18 veterinary medicine licensed to practice his profession, or pharmacists licensed to  
19 practice their profession; physician's assistants certified to practice their profession;  
20 government employees acting within the scope of their employment; and persons  
21 permitted by certificates issued by the Department of Health to distribute, dispense,  
22 conduct research with respect to, or administer a substance controlled by chapter  
23 34-20B;
- 24 (9) "Precursor" or "immediate precursor," a substance which the Department of Health  
25 has found to be and by rule designates as being a principal compound commonly  
26 used or produced primarily for use, and which is an immediate chemical  
27 intermediary used or likely to be used, in the manufacture of a controlled drug or  
28 substance, the control of which is necessary to prevent, curtail, or limit such  
29 manufacture;
- 30 (10) "Schedule I," "Schedule II," "Schedule III," and "Schedule IV," those schedules of  
31 drugs, substances, and immediate precursors listed in chapter 34-20B;
- 32 (11) "Ultimate user," a person who lawfully possesses a controlled drug or substance for  
33 that person's own use or for the use of a member of that person's household or for  
34 administration to an animal owned by that person or by a member of that person's  
35 household.

1 **Section 23.** That § 34-20B-1 be AMENDED:

2 **34-20B-1. Definitions.**

3 Terms as used in this chapter mean:

- 4 (1) "Administer," to deliver a controlled drug or substance to the ultimate user or  
5 human research subject by injection, inhalation, or ingestion, or by any other  
6 means;
- 7 (2) "Agent," an authorized person who acts on behalf of or at the direction of a  
8 manufacturer, distributor, or dispenser and includes a common or contract carrier,  
9 public warehouseman, or employee thereof;
- 10 (3) "Control," to add, remove, or change the placement of a drug, substance, or  
11 immediate precursor under §§ 34-20B-27 and 34-20B-28;
- 12 (4) "Counterfeit substance," a controlled drug or substance which, or the container or  
13 labeling of which, without authorization, bears the trademark, trade name, or other  
14 identifying mark, imprint, number, or device, or any likeness thereof, of a  
15 manufacturer, distributor, or dispenser other than the person or persons who  
16 manufactured, distributed, or dispensed such substance and which thereby falsely  
17 purports or is represented to be the product of, or to have been distributed by, such  
18 other manufacturer, distributor, or dispenser;
- 19 (5) "Deliver" or "delivery," the actual, constructive, or attempted transfer of a  
20 controlled drug, substance, or marijuana whether or not there exists an agency  
21 relationship;
- 22 (6) "Department," the Department of Health created by chapter 1-43;
- 23 (7) "Dispense," to deliver a controlled drug or substance to the ultimate user or human  
24 research subject by or pursuant to the lawful order of a practitioner, including the  
25 prescribing, administering, packaging, labeling, or compounding necessary to  
26 prepare the substance for such delivery, and a dispenser is one who dispenses;
- 27 (8) "Distribute," to deliver a controlled drug, substance, or marijuana. A distributor is  
28 a person who delivers a controlled drug, substance, or marijuana;
- 29 (9) "Hashish," the resin extracted from any part of any plant of the genus cannabis,  
30 ~~commonly known as the marijuana plant~~ that contains a delta-9  
31 tetrahydrocannabinol concentration of more than three-tenths of one percent on a  
32 dry weight basis;
- 33 (10) "Imprisonment," imprisonment in the state penitentiary unless the penalty  
34 specifically provides for imprisonment in the county jail;

- 1 (11) "Manufacture," the production, preparation, propagation, compounding, or  
2 processing of a controlled drug or substance, either directly or indirectly by  
3 extraction from substances of natural origin, or independently by means of chemical  
4 synthesis or by a combination of extraction and chemical synthesis. A manufacturer  
5 includes any person who packages, repackages, or labels any container of any  
6 controlled drug or substance, except practitioners who dispense or compound  
7 prescription orders for delivery to the ultimate consumer;
- 8 (12) "Marijuana," all parts of any plant of the genus cannabis, whether growing or not;  
9 the seeds thereof; and every compound, manufacture, salt, derivative, mixture, or  
10 preparation of such plant or its seeds. The term does not include fiber produced  
11 from the mature stalks of the plant, or oil or cake made from the seeds of the plant,  
12 or the resin when extracted from any part of the plant or cannabidiol, in a drug  
13 product approved by the United States Food and Drug Administration. The term  
14 does not include the plant Cannabis sativa L. and any part of that plant, including  
15 the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts,  
16 and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol  
17 concentration of not more than three-tenths of one percent on a dry weight basis;
- 18 (13) "Narcotic drug," any of the following, whether produced directly or indirectly by  
19 extraction from substances of vegetable origin or independently by means of  
20 chemical synthesis, or by a combination of extraction and chemical synthesis:  
21 (a) Opium, coca leaves, and opiates;  
22 (b) A compound, manufacture, salt, derivative, or preparation of opium, coca  
23 leaves, or opiates;  
24 (c) A substance (and any compound, manufacture, salt, derivative, or  
25 preparation thereof) which is chemically identical with any of the substances  
26 referred to in subsections (a) and (b) of this subdivision;  
27 except that the term, narcotic drug, as used in this chapter does not include  
28 decocainized coca leaves or extracts of coca leaves, which extracts do not contain  
29 cocaine or ecgonine;
- 30 (14) "Opiate" or "Opioid," any controlled drug or substance having an addiction-  
31 sustaining liability similar to morphine or being capable of conversion into a drug  
32 having such addiction-forming or addiction-sustaining liability;
- 33 (15) "Opium poppy," the plant of the species papaver somniferum L., except the seeds  
34 thereof;

- 1 (16) "Person," any corporation, association, limited liability company, partnership or one  
2 or more individuals;
- 3 (17) "Poppy straw," all parts, except the seeds, of the opium poppy, after mowing;
- 4 (18) "Practitioner," a doctor of medicine, osteopathy, podiatry, optometry, dentistry, or  
5 veterinary medicine licensed to practice their profession, or pharmacists licensed to  
6 practice their profession; physician assistants certified to practice their profession;  
7 certified nurse practitioners and certified nurse midwives to practice their  
8 profession; government employees acting within the scope of their employment;  
9 and persons permitted by certificates issued by the department to distribute,  
10 dispense, conduct research with respect to, or administer a substance controlled by  
11 this chapter;
- 12 ~~(18A)~~(19) "Prescribe," an order of a practitioner for a controlled drug or substance.
- 13 ~~(19)~~(20) "Production," the manufacture, planting, cultivation, growing, or harvesting  
14 of a controlled drug or substance;
- 15 ~~(20)~~(21) "State," the State of South Dakota;
- 16 ~~(21)~~(22) "Ultimate user," a person who lawfully possesses a controlled drug or  
17 substance for personal use or for the use of a member of the person's household or  
18 for administration to an animal owned by the person or by a member of the person's  
19 household;
- 20 ~~(22)~~(23) "Controlled substance analogue," any of the following:
- 21 (a) A substance that differs in its chemical structure to a controlled substance  
22 listed in or added to the schedule designated in schedule I or II only by  
23 substituting one or more hydrogens with halogens or by substituting one  
24 halogen with a different halogen; or
- 25 (b) A substance that is an alkyl homolog of a controlled substance listed in or  
26 added to schedule I or II; or
- 27 (c) A substance intended for human consumption; and
- 28 (i) The chemical structure of which is substantially similar to the chemical  
29 structure of a controlled substance in schedule I or II;
- 30 (ii) Which has a stimulant, depressant, or hallucinogenic effect on the  
31 central nervous system that is substantially similar to or greater than  
32 the stimulant, depressant, or hallucinogenic effect on the central  
33 nervous system of a controlled substance in schedule I or II; or
- 34 (iii) With respect to a particular person, which such person represents or  
35 intends to have a stimulant, depressant, or hallucinogenic effect on the

1 central nervous system that is substantially similar to or greater than  
2 the stimulant, depressant, or hallucinogenic effect on the central  
3 nervous system of a controlled substance in schedule I or II;

4 However, the term, controlled substance analogue, does not include a controlled  
5 substance or any substance for which there is an approved new drug application.

6 **Section 24.** That § 34-20B-14 be AMENDED:

7 **34-20B-14. Hallucinogenic substances specifically included in Schedule I.**

8 Any material, compound, mixture, or preparation which contains any quantity of  
9 the following hallucinogenic substances, their salts, isomers, and salts of isomers, is  
10 included in Schedule I, unless specifically excepted, whenever the existence of such salts,  
11 isomers, and salts of isomers is possible within the specific chemical designation:

- 12 (1) Bufotenine;
- 13 (2) Diethyltryptamine (DET);
- 14 (3) Dimethyltryptamine (DMT);
- 15 (4) 5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT);
- 16 (5) 5-methoxy-3, 4-methylenedioxy amphetamine;
- 17 (6) 4-bromo-2, 5-dimethoxyamphetamine;
- 18 (7) 4-methoxyamphetamine;
- 19 (8) 4-methoxymethamphetamine;
- 20 (9) 4-methyl-2, 5-dimethoxyamphetamine;
- 21 (10) Hashish and hash oil;
- 22 (11) Ibogaine;
- 23 (12) Lysergic acid diethylamide;
- 24 (13) Mescaline;
- 25 (14) N-ethyl-3-piperidyl benzilate;
- 26 (15) N-methyl-3-piperidyl benzilate;
- 27 (16) 1-(-(2-thienyl)cyclohexyl) piperidine (TCP);
- 28 (17) Peyote, except that when used as a sacramental in services of the Native American  
29 church in a natural state which is unaltered except for drying or curing and cutting  
30 or slicing, it is hereby excepted;
- 31 (18) Psilocybin;
- 32 (19) Psilocyn;
- 33 (20) Tetrahydrocannabinol, other than that which occurs in industrial hemp as defined  
34 in § 38-35-1 or marijuana in its natural and unaltered state, including any



1 compound, except nabilone or compounds listed under a different schedule,  
2 structurally derived from 6,6N dimethyl-benzo[c]chromene by substitution at the  
3 3-position with either alkyl (C3 to C8), methyl cycloalkyl, or adamantyl groups,  
4 whether or not the compound is further modified in any of the following ways:

- 5 (a) By partial to complete saturation of the C-ring; or
- 6 (b) By substitution at the 1-position with a hydroxyl or methoxy group; or
- 7 (c) By substitution at the 9-position with a hydroxyl, methyl, or methylhydroxyl  
8 group; or
- 9 (d) By modification of the possible 3-alkyl group with a 1,1N dimethyl moiety, a  
10 1,1N cyclic moiety, an internal methylene group, an internal acetylene group,  
11 or a terminal halide, cyano, azido, or dimethylcarboxamido group.

12 Some trade and other names: JWH-051; JWH-057; JWH-133; JWH-359; HHC; AM-  
13 087; AM-411; AM-855, AM-905; AM-906; AM-2389; HU-210; HU-211; HU-243;  
14 HU-336;

- 15 (21) 3, 4, 5-trimethoxy amphetamine;
- 16 (22) 3, 4-methylenedioxy amphetamine;
- 17 (23) 3-methoxyamphetamine;
- 18 (24) 2, 5-dimethoxyamphetamine;
- 19 (25) 2-methoxyamphetamine;
- 20 (26) 2-methoxymethamphetamine;
- 21 (27) 3-methoxymethamphetamine;
- 22 (28) Phencyclidine;
- 23 (29) 3, 4-methylenedioxy methamphetamine (MDMA);
- 24 (30) 3, 4-methylenedioxy-N-ethylamphetamine;
- 25 (31) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 26 (32) 4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline);
- 27 (33) 2,5 Dimethoxy-4-ethylamphetamine;
- 28 (34) N,N-Dimethylamphetamine;
- 29 (35) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine;
- 30 (36) Aminorex;
- 31 (37) Cathinone and other variations, defined as any compound, material, mixture,  
32 preparation or other product unless listed in another schedule or an approved FDA  
33 drug (e.g. bupropion, pyrovalerone), structurally derived from 2-aminopropan-1-  
34 one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring

1 systems, whether or not the compound is further modified in any of the following  
2 ways:

- 3 (a) By substitution in the ring system to any extent with alkyl, alkylendioxy,  
4 alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further  
5 substituted in the ring system by one or more other univalent substituents;  
6 (b) By substitution at the 3-position with an acyclic alkyl substituent;  
7 (c) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or  
8 methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a cyclic  
9 structure.

10 Some trade or other names: methcathinone, 4-methyl-N-methylcathinone  
11 (mephedrone); 3,4-methylenedioxy-N-methylcathinone (methydone); 3,4-  
12 methylenedioxypropylvalerone (MDPV); Naphthylpropylvalerone (naphyrone); 4-  
13 fluoromethcathinone (flephedrone); 4-methoxymethcathinone (methedrone; Bk-  
14 PMMA); Ethcathinone (N-Ethylcathinone); 3,4-methylenedioxyethcathinone  
15 (ethylone); Beta-keto-N-methyl-3,4-benzodioxolylbutanamine (butylone); N,N-  
16 dimethylcathinone (metamfepramone); Alpha-pyrrolidinopropiophenone (alpha-  
17 PPP); 4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP); 3,4-  
18 methylenedioxyalpha-pyrrolidinopropiophenone (MDPPP); Alpha-  
19 pyrrolidinovalerophenone (alpha-PVP); 3-fluoromethcathinone; 4N-Methyl-alpha-  
20 pyrrolidinobutiophenone (MPBP); Methyl-~~α~~-pyrrolidinopropiophenone  
21 (MPPP); Methyl-~~α~~-pyrrolidino-hexanophenone (MPHP); Buphedrone; Methyl-  
22 N-ethylcathinone; Pentedrone; Dimethylmethcathinone (DMMC);  
23 Dimethylethcathinone (DMEC); Methylenedioxy-methcathinone (MDMC); Pentylone;  
24 Ethylethcathinone; Ethylmethcathinone; Fluoroethcathinone; methyl-alpha-  
25 pyrrolidinobutiophenone (MPBP); Methylecathinone (MEC); Methylenedioxy-alpha-  
26 pyrrolidinobutiophenone (MDPBP); Methoxymethcathinone (MOMC);  
27 Methylbuphedrone (MBP); Benzedrone (4-MBC); Dibutylone (DMBDB);  
28 Dimethylone (MDDMA); Diethylcathinone; Eutylone (EBDB); N-ethyl-N-  
29 Methylcathinone; N-ethylbuphedrone, 1-(1,3-benzodioxol-5-yl)2-  
30 (ethylamino)pentan-1-one (N-Ethylpentylone); 4'-Methyl-alpha-  
31 pyrrolidinopropiophenone (4-MEPPP, MPPP or MaPPP); alpha-  
32 Pyrrolidinobutiophenone (α;PBP); 1-(1,3-benzodioxol-5-yl)-2-(tert-  
33 butylamino)propan-1-one (Tertylone); 1-(1,3-benzodioxol-5-yl)-2-  
34 (ethylamino)hexan-1-one (N-ethyl Hexylone);  
35 (38) 2,5-Dimethoxy-4-ethylamphetamine (DOET);

- 1 (39) Alpha-ethyltryptamine;
- 2 (40) 4-Bromo-2,5-dimethoxy phenethylamine;
- 3 (41) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);
- 4 (42) 1-(3-trifluoromethylphenyl) piperazine (TFMPP);
- 5 (43) Alpha-methyltryptamine (AMT);
- 6 (44) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 7 (45) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 8 (46) Synthetic cannabinoids. Any material, compound, mixture, or preparation that is
- 9 not listed as a controlled substance in another schedule, is not an FDA-approved
- 10 drug, and contains any quantity of the following substances, their salts, isomers
- 11 (whether optical, positional, or geometric), homologues, modifications of the indole
- 12 ring by nitrogen heterocyclic analog substitution or nitrogen heterocyclic analog
- 13 substitution of the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, cumyl, or
- 14 propionaldehyde structure, and salts of isomers, homologues, and modifications,
- 15 unless specifically excepted, whenever the existence of these salts, isomers,
- 16 homologues, modifications, and salts of isomers, homologues, and modifications is
- 17 possible within the specific chemical designation:
- 18 (a) Naphthoylindoles. Any compound containing a 2-(1-naphthoyl)indole or 3-
- 19 (1-naphthoyl)indole structure with substitution at the nitrogen atom of the
- 20 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
- 21 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalkyl, 1-
- 22 (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
- 23 (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not
- 24 further substituted on the indole ring to any extent and whether or not
- 25 substituted on the naphthyl ring to any extent.
- 26 Some trade or other names: JWH-015; 1-pentyl-3-(1-naphthoyl)indole
- 27 (JWH-018); 1-hexyl-3-(1-naphthoyl)indole (JWH-019); 1-butyl-3-(1-
- 28 naphthoyl)indole (JWH-073); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole
- 29 (JWH-081); 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); 1-[2-(4-
- 30 morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); JWH-210; JWH-398;
- 31 1-pentyl-3-(1-naphthoyl)indole (AM-678); 1-(5-fluoropentyl)-3-(1-
- 32 naphthoyl)indole (AM-2201); WIN 55-212; JWH-004; JWH-007; JWH-009;
- 33 JWH-011; JWH-016; JWH-020; JWH-022; JWH-046; JWH-047; JWH-048;
- 34 JWH-049; JWH-050; JWH-070; JWH-071; JWH-072; JWH-076; JWH-079;
- 35 JWH-080; JWH-082; JWH-094; JWH-096; JWH-098; JWH-116; JWH-120;

- 1 JWH-148; JWH-149; JWH-164; JWH-166; JWH-180; JWH-181; JWH-182;  
2 JWH-189; JWH-193; JWH-198; JWH-211; JWH-212; JWH-213; JWH-234;  
3 JWH-235; JWH-236; JWH-239; JWH-240; JWH-241; JWH-258; JWH-262;  
4 JWH-386; JWH-387; JWH-394; JWH-395; JWH-397; JWH-399; JWH-400;  
5 JWH-412; JWH-413; JWH-414; JWH-415; JWH-424; AM-678; AM-1220; AM-  
6 1221; AM-1235; AM-2232, THJ-2201;
- 7 (b) Naphthylmethyloindoles. Any compound containing a 1H-indol-2-yl-(1-  
8 naphthyl)methane or 1H-indol-3-yl-(1-naphthyl)methane structure with  
9 substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,  
10 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,  
11 2-(4-morpholinyl)ethyl, cyanoalkyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-  
12 methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or  
13 halobenzyl group, whether or not further substituted on the indole ring to any  
14 extent and whether or not substituted on the naphthyl ring to any extent.  
15 Some trade or other names: JWH-175; JWH-184; JWH-185; JWH-192; JWH-  
16 194; JWH-195; JWH-196; JWH-197; JWH-199;
- 17 (c) Phenylacetyloindoles. Any compound containing a 2-phenylacetyloindole or 3-  
18 phenylacetyloindole structure with substitution at the nitrogen atom of the  
19 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
20 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalkyl, 1-  
21 (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,  
22 (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not  
23 further substituted on the indole ring to any extent and whether or not  
24 substituted on the phenyl ring to any extent.  
25 Some trade or other names: 1-cyclohexylethyl-3-(2-  
26 methoxyphenylacetyl)indole (SR-18); 1-cyclohexylethyl-3-(2-  
27 methoxyphenylacetyl)indole (RCS-8); 1-pentyl-3-(2-  
28 methoxyphenylacetyl)indole (JWH-250); 1-pentyl-3-(2-  
29 chlorophenylacetyl)indole (JWH-203); JWH-167; JWH-201; JWH-202; JWH-  
30 204; JWH-205; JWH-206; JWH-207; JWH-208; JWH-209; JWH-237; JWH-  
31 248; JWH-249; JWH-251; JWH-253; JWH-302; JWH-303; JWH-304; JWH-  
32 305; JWH-306; JWH-311; JWH-312; JWH-313; JWH-314; JWH-315; JWH-  
33 316; Cannabipiperidiethanone;
- 34 (d) Benzoyloindoles. Any compound containing a 2-(benzoyl)indole or 3-  
35 (benzoyl)indole structure with substitution at the nitrogen atom of the indole

1 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-  
2 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalkyl, 1-(N-  
3 methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,  
4 (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not  
5 further substituted on the indole ring to any extent and whether or not  
6 substituted on the phenyl ring to any extent.

7 Some trade or other names: 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-  
8 694); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19); Pravadoline (WIN  
9 48,098); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4); AM-630; AM-  
10 661; AM-2233; AM-1241;

- 11 (e) Naphthoylpyrroles. Any compound containing a 2-(1-naphthoyl)pyrrole or 3-  
12 (1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the  
13 pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
14 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalkyl, 1-(N-  
15 methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,  
16 (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not  
17 further substituted on the pyrrole ring to any extent and whether or not  
18 substituted on the naphthyl ring to any extent.

19 Some trade or other names: JWH-307; JWH-030; JWH-031; JWH-145; JWH-  
20 146; JWH-147; JWH-150; JWH-156; JWH-242; JWH-243; JWH-244; JWH-  
21 245; JWH-246; JWH-292; JWH-293; JWH-308; JWH-309; JWH-346; JWH-  
22 348; JWH-363; JWH-364; JWH-365; JWH-367; JWH-368; JWH-369; JWH-  
23 370; JWH-371; JWH-373; JWH-392;

- 24 (f) Naphthylmethylindenes. Any compound containing a naphthylideneindene  
25 structure with substitution at the 3-position of the indene ring by an alkyl,  
26 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
27 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalkyl, 1-(N-methyl-2-  
28 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-  
29 yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on  
30 the indene ring to any extent and whether or not substituted on the naphthyl  
31 ring to any extent.

32 Some trade or other names: JWH-171; JWH-176; JWH-220;

- 33 (g) Cyclohexylphenols. Any compound containing a 2-(3-  
34 hydroxycyclohexyl)phenol structure with substitution at the 5-position of the  
35 phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,

- 1 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 1-(N-methyl-  
2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-  
3 4-yl)methyl, benzyl, or halobenzyl group, whether or not substituted on the  
4 cyclohexyl ring to any extent.
- 5 Some trade or other names: 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-  
6 hydroxycyclohexyl]-phenol (CP 47, 497 and homologues, which includes C8);  
7 cannabicyclohexanol; CP-55,490; CP-55,940; CP-56,667
- 8 (h) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)  
9 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Some trade or other names:  
10 HU-210;
- 11 (i) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-  
12 benzoxazin-6-yl]-1-naphthalenyl. Some trade or other names: WIN 55, 212-  
13 2;
- 14 (j) Substituted Acetylindoles. Any compound containing a 2-acetyl indole or 3-  
15 acetyl indole structure substituted at the acetyl by replacement of the methyl  
16 group with a tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or  
17 propionaldehyde substituent whether or not further substituted on the  
18 tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or propionaldehyde  
19 substituent to any extent and whether or not further substituted at the  
20 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,  
21 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-  
22 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
23 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl  
24 group whether or not further substituted on the indole ring to any extent.  
25 Some trade and or names: (1-Pentylindol-3-yl)-(2,2,3,3-  
26 tetramethylcyclopropyl)methanone (UR-144); (1-(5-fluoropentyl)indol-3-  
27 yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11); (1-(2-morpholin-  
28 4-ylethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (A-  
29 796,260); 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole  
30 (AM-1248); 1-Pentyl-3-(1-adamantoyl)indole (AB-001 and JWH-018  
31 adamantyl analog); AM-679;
- 32 (k) Substituted Carboxamide Indole. Any compound containing a 2-carboxamide  
33 indole or 3-carboxamide indole structure substituted at the nitrogen of the  
34 carboxamide with a tetramethylcyclopropyl, naphthyl, adamantyl, cumyl,  
35 phenyl, or propionaldehyde substituent, whether or not further substituted

1 on the tetramethylcyclopropyl, adamantyl, cumyl, naphthyl, phenyl, or  
2 propionaldehyde substituent to any extent and whether or not further  
3 substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl,  
4 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
5 piperidiny) methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
6 pyrrolidiny) methyl, 1-(N-methyl-3-morpholinyl) methyl, (tetrahydropyran-4-  
7 yl) methyl, benzyl, or halobenzyl group whether or not further substituted on  
8 the indole ring to any extent.

9 Some trade and other names: JWH-018 adamantyl carboxamide; STS-135;  
10 MN-18; 5-Fluoro-MN-18, 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-  
11 pyrrolo[2,3-b]pyridine-3-carboxamide (5F-CUMYL-P7AICA); N-(Adamantan-  
12 1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA); methyl  
13 (2R)-2-[[1-(5-fluoropentyl)indazole-3-carbonyl]amino]-3,3-  
14 dimethylbutanoate (5F-ADB); N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-  
15 (cyclohexylmethyl)indazole-3-carboxamide (AB-CHMINACA); 1-(4-  
16 cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (4-CN-  
17 CUMYL-BUTINACA); methyl (2R)-2-[[1-(5-fluoropentyl)indazole-3-  
18 carbonyl]amino]-3,3-dimethylbutanoate (5F-ADB); N-(1-amino-3,3-  
19 dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide  
20 (ADB-CHMINACA or MAB-CHMINACA); methyl (2S)-2-[[1-[4-  
21 fluorophenyl)methyl]indazole-3-carbonyl]amino]-3,3-dimethylbutanoate  
22 (MDMB-FUBINACA); methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-  
23 carboxamido)-3-methylbutanoate (MMB-CHMICA); methyl (2S)-2-[[1-[4-  
24 fluorophenyl)methyl]indazole-3-carbonyl]amino]-3-methylbutanoate (AMB-  
25 FUBINACA); Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-  
26 methylbutanoate (5F-AMB);

- 27 (I) Substituted Carboxylic Acid Indole. Any compound containing a 1H-indole-2-  
28 carboxylic acid or 1H-indole-3-carboxylic acid substituted at the hydroxyl  
29 group of the carboxylic acid with a phenyl, benzyl, naphthyl, adamantyl,  
30 cyclopropyl, quinolinyl, isquinolinyl, cumyl, or propionaldehyde substituent  
31 whether or not further substituted on the phenyl, benzyl, naphthyl,  
32 adamantyl, cyclopropyl, cumyl, quinolinyl, isquinolinyl, or propionaldehyde  
33 substituent to any extent and whether or not further substituted at the  
34 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,  
35 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny) methyl, 2-(4-

1 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
2 morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group  
3 whether or not further substituted on the indole ring to any extent.

4 Some trade and other names: Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-  
5 3-carboxylate (NM2201);

6 (47) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI);

7 (48) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);

8 (49) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);

9 (50) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

10 (51) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

11 (52) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);

12 (53) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);

13 (54) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);

14 (55) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);

15 (56) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);

16 (57) Substituted phenethylamine. Any compound, unless specifically exempt, listed as a  
17 controlled substance in another schedule or an approved FDA drug, structurally  
18 derived from phenylethan-2-amine by substitution on the phenyl ring in any of the  
19 following ways, that is to say--by substitution with a fused methylenedioxy, fused  
20 furan, or fused tetrahydrofuran ring system; by substitution with two alkoxy  
21 groups; by substitution with one alkoxy and either one fused furan,  
22 tetrahydrofuran, or tetrahydropyran ring system; by substitution with two fused  
23 ring systems from any combination of the furan, tetrahydrofuran, or  
24 tetrahydropyran ring systems; whether or not the compound is further modified in  
25 any of the following ways:

26 (a) By substitution on the phenyl ring by any halo, hydroxyl, alkyl,  
27 trifluoromethyl, alkoxy, or alkylthio groups;

28 (b) By substitution on the 2-position by any alkyl groups; or

29 (c) By substitution on the 2-amino nitrogen atom with acetyl, alkyl, dialkyl,  
30 benzyl, methoxybenzyl, or hydroxybenzyl groups.

31 Some trade and other names: 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine  
32 (2C-T or 4-methylthio-2,5-dimethoxyphenethylamine); 1-(2,5-dimethoxy-4-  
33 iodophenyl)-propan-2-amine (DOI or 2,5-Dimethoxy-4-iodoamphetamine); 1-(4-  
34 Bromo-2,5-dimethoxyphenyl)-2-aminopropane (DOB or 2,5-Dimethoxy-4-  
35 bromoamphetamine); 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine (DOC or



- 1 2,5-Dimethoxy-4-chloroamphetamine); 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-  
2 methoxyphenyl)methyl]ethanamine (2C-B-NBOMe; 25B-NBOMe or 2,5-Dimethoxy-  
3 4-bromo-N-(2-methoxybenzyl)phenethylamine); 2-(4-iodo-2,5-dimethoxyphenyl)-  
4 N-[(2-methoxyphenyl)methyl]ethanamine (2C-I-NBOMe; 25I-NBOMe or 2,5-  
5 Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine); N-(2-Methoxybenzyl)-  
6 2-(3,4,5-trimethoxyphenyl)ethanamine (Mescaline-NBOMe or 3,4,5-trimethoxy-(2-  
7 methoxybenzyl)phenethylamine); 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-  
8 methoxyphenyl)methyl]ethanamine (2C-C-NBOMe; 25C-NBOMe or 2,5-Dimethoxy-  
9 4-chloro-N-(2-methoxybenzyl)phenethylamine); 2-(7-Bromo-5-methoxy-2,3-  
10 dihydro-1-benzofuran-4-yl)ethanamine (2CB-5-hemiFLY); 2-(8-bromo-2,3,6,7-  
11 tetrahydrofuro[2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-FLY); 2-(10-Bromo-  
12 2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-yl)ethanamine (2C-B-butterFLY);  
13 -(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-bN]difuran-4-  
14 yl)-2-aminoethane (2C-B-FLY-NBOMe); 1-(4-Bromofuro[2,3-f][1]benzofuran-8-  
15 yl)propan-2-amine (bromo-benzodifuranyl-isopropylamine or bromo-dragonFLY); -  
16 (2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine (2C-I-NBOH or 25I-  
17 NBOH); 5-(2-Aminopropyl)benzofuran (5-APB); 6-(2-Aminopropyl)benzofuran (6-  
18 APB); 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB); 6-(2-Aminopropyl)-  
19 2,3-dihydrobenzofuran (6-APDB);
- 20 (58) Substituted tryptamines. Any compound, unless specifically exempt, listed as a  
21 controlled substance in another schedule or an approved FDA drug, structurally  
22 derived from 2-(1H-indol-3-yl)ethanamine (i.e, tryptamine) by mono- or di-  
23 substitution of the amine nitrogen with alkyl or alkenyl groups or by inclusion of the  
24 amino nitrogen atom in a cyclic structure whether or not the compound is further  
25 substituted at the alpha-position with an alkyl group or whether or not further  
26 substituted on the indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl,  
27 or acetoxy groups.
- 28 Some trade and other names: 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT); 4-  
29 acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or O-Acetylpsilocin); 4-hydroxy-N-  
30 methyl-N-ethyltryptamine (4-HO-MET); 4-hydroxy-N,N-diisopropyltryptamine (4-  
31 HO-DIPT); 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MIPT);
- 32 (59) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (CB-13);  
33 (60) N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide (AKB 48);  
34 (61) 1-(4-Fluorophenyl)piperazine (pFPP);  
35 (62) 1-(3-Chlorophenyl)piperazine (mCPP);

- 1 (63) 1-(4-Methoxyphenyl)piperazine (pMeOPP);  
2 (64) 1,4-Dibenzylpiperazine (DBP);  
3 (65) Isopentadrone;  
4 (66) Fluoromethamphetamine;  
5 (67) Fluoroamphetamine;  
6 (68) Fluorococaine;  
7 (69) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);  
8 (70) 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (5 Fluoro-PB-22);  
9 (71) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-  
10 PINACA);  
11 (72) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-  
12 carboxamide (5 Fluoro-AB-PINACA);  
13 (73) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-  
14 carboxamide (AB-FUBINACA);  
15 (74) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide  
16 (ADB-PINACA (ADBICA));  
17 (75) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-  
18 carboxamide (5 Fluoro-ADB-PINACA (5 Fluoro-ADBICA)); and  
19 (76) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-  
20 carboxamide (ADB-FUBINACA).

21 **Section 25.** There is hereby appropriated from the general fund the sum of thirty-six  
22 thousand five hundred eighty-six dollars (\$36,586), or so much thereof as may be necessary,  
23 to the Department of Agriculture, ~~the sum of seven hundred five thousand seven hundred~~  
24 ~~dollars (\$705,700) to the Department of Health, and the sum of one million one hundred fifty-~~  
25 ~~seven thousand five hundred seventeen dollars (\$1,157,517) in other fund expenditure~~  
26 ~~authority to the Department of Public Safety, or so much thereof as may be necessary, for~~  
27 ~~the purpose of funding this Act.~~

28 **Section 26.** There is hereby appropriated from the general fund the sum of seven hundred  
29 five thousand seven hundred dollars (\$705,700), or so much thereof as may be necessary,  
30 to the Department of Health.

31 **Section 27.** There is hereby appropriated the sum of one million one hundred fifty-seven  
32 thousand five hundred seventeen dollars (\$1,157,517) in other fund expenditure authority,  
33 or so much thereof as may be necessary, to the Department of Public Safety.

1 **Section 28.** The secretary of the Department of Agriculture shall approve vouchers and the  
2 state auditor shall draw warrants to pay expenditures authorized in section 25 of this Act.

3 **Section 29.** The secretary of the Department of Health shall approve vouchers and the state  
4 auditor shall draw warrants to pay expenditures authorized in section 26 of this Act.

5 **Section 30.** The secretary of the Department of Public Safety shall approve vouchers and the  
6 state auditor shall draw warrants to pay expenditures authorized in section 27 of this Act.

7 **Section 31.** Any amounts appropriated in this Act not lawfully expended or obligated shall  
8 revert in accordance with the procedures prescribed in chapter 4-8.

9 ~~**Section 32.** Expenditures for this Act shall be made by an appropriation of the~~  
10 ~~Legislature through either the general appropriations act or a special appropriations~~  
11 ~~bill.~~

12 **Section 32.** Whereas, this Act is necessary for the support of the state government and its  
13 existing public institutions, an emergency is hereby declared to exist, and this Act shall be in  
14 full force and effect from and after its passage and approval.